Endo’s generics revenues slid during the first quarter but a sharp jump in sterile injectables sales helped the company to slash its net loss from a year earlier and beat analysts’ earnings forecasts.
Endo’s chief executive, Paul Campanelli, who is steering the firm’s turnaround, said he was not worried by the fall in...







